Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeepTag-GPRC5D CAR-T in RRMM
NCT06084962Phase 1Recruiting
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DeepTag-GPRC5D targeted CAR T-cells in multiple myeloma (MM). Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 2 years. Started Oct 2023; status: recruiting.
02
Drugs
DeepTag-GPRC5D targeted CAR T-cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06084962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06084962.